Kolon TissueGene, Inc. (KOSDAQ:950160)

Market Cap	3.20T
Revenue (ttm)	5.15B
Net Income (ttm)	-35.85B
Shares Out	83.00M
EPS (ttm)	-452.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	130,857
Average Volume	225,231
Open	38,500
Previous Close	38,500
Day's Range	38,250 - 40,050
52-Week Range	13,190 - 59,300
Beta	-0.81
RSI	42.79
Earnings Date	n/a

About Kolon TissueGene

Kolon TissueGene, Inc. develops cell therapies for orthopedic diseases and other unmet medical needs. The company’s lead product is the TG-C that has completed Phase II trials to treat osteoarthritis, as well as rheumatoid arthritis, meniscus, and spinal discs. It is also developing cell therapies for musculoskeletal system disorders, as well as vet medicine. Kolon TissueGene, Inc. was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018. The company was founded in 1999 and is headquartered in Rockvill...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 29
• Stock Exchange: KOSDAQ
• Ticker Symbol: 950160

Financial Performance

In 2024, Kolon TissueGene's revenue was 5.07 billion, an increase of 36.90% compared to the previous year's 3.71 billion. Losses were -33.80 billion, 96.2% more than in 2023.